Greenwich LifeSciences (GLSI) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 37.0% versus a gain of 13.0%. Over five years, IFRX leads with a -36.8% price change compared with -59.5% for GLSI. InflaRx N.V. is the larger company by market cap ($229.9 million vs $225.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | IFRX |
|---|---|---|
| Share price | $15.39 | $1.56 |
| Market cap | $225.90M | $229.89M |
| 1-day change | -2.53% | -1.27% |
| YTD return | -26.75% | +54.46% |
| 1-year return | +37.04% | +13.04% |
| 5-year return | -59.46% | -36.84% |
| EPS (TTM) | $-1.49 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $2.95 |
| 52-week low | $7.78 | $0.798 |
| Distance from 52-week high | -54.87% | -47.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +270.37% | +391.03% |
| Average volume | 138.58K | 799.42K |
| Shares outstanding | 14.68M | 147.37M |
| Employees | — | 65 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed IFRX by 24.0 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Healthcare · Biotechnology
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
GLSI vs IFRX FAQ
Which is bigger, Greenwich LifeSciences or InflaRx N.V.?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $229.89M compared with $225.90M for Greenwich LifeSciences (GLSI).
Which stock has performed better over the past year, GLSI or IFRX?
GLSI returned +37.04% over the past 12 months, compared with +13.04% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.